International ID Day: Thales Stands up for a Legal and Trusted Identity for Everyone
16.9.2024 08:00:00 CEST | Business Wire | Press release
On the International Identity Day ‘ID Day’, Thales reaffirms its dedication to supporting global identity initiatives and driving technological advancements that foster inclusion, security, and trust. Around the world, more than 850 million individuals do not have a legal identity, preventing them from claiming their rights and accessing fundamental citizen services e.g. health, education, employment. Thales has been working for more than thirty years to make trustworthy identities a reality for everyone, employing cutting-edge and responsible technology for biometrics and digital ID solutions.
On September 16th, Thales celebrates the International Identity Day (ID Day), a symbolic day to highlight the United Nations' Sustainable Development Goal16.9 to provide a legal identity for all. ID Day is dedicated to raising awareness about the importance of legal identity as a fundamental human right and a key enabler of inclusive social and economic development. Thales supports global efforts to guarantee every individual has access to a secure and trusted identity.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240915417415/en/
(Photo: Thales)
Thales, a leading provider of secure physical and biometrics identification, has been actively involved in projects that are in line with the UN's Sustainable Development Goal 16.9, including birth registration, by 2030. According to the 2023 estimates from the World Bank's Identification for Development (ID4D) Initiative, over 850 million people globally lack an official ID. Thanks to global mobilization, the overall situation has improved since 2020 when 1 billion individuals were missing a legal ID.
ID Day highlights the significance of having a legal identity and the positive impact it has on individuals and communities worldwide. A legal identity grants access to essential services, fosters social inclusion, and facilitates participation in the global economy. That is why Thales, recognised as the number one digital identity player by Juniper Research (in its “2024 Juniper Research Competitor Leaderboard”) stands for a future in which everyone could benefit from and confirm their trusted identity, leaving no one behind.
"ID Day serves as a crucial reminder that identity is a fundamental human right. In today's interconnected world, having a secure and trusted legal ID is essential for accessing services, exercising rights, and fostering economic development. At Thales, we are committed to driving innovation in biometric and digital identity solutions, ensuring that every individual can claim their rightful place in society. Our goal is to support with our solutions a world where identity is secure, inclusive, and universally recognized," said Youzec Kurp, VP Identity and Biometrics Solutions at Thales Group.
A secure identity is more than just a document; it is a gateway to opportunities and a cornerstone of trust in the digital age. Thales responsible biometrics (cfTrUE Biometrics1) and digital ID solutions are designed to meet the highest security standards, protecting individuals' personal data while facilitating seamless access to services as well as mobility.
1TrUE Biometrics stands for Transparent, Understandable and finally Ethical. For years, Thales has developed highly secure solutions and biometrics has proved its full capacity to offer both security and convenience. While the technology serves a wide range of new needs triggered by our societies' digital transformation, Thales also supports initiatives that raise awareness of the benefits and risks of adopting biometric identification technologies. Thales is a reliable and responsible partner since it provides transparent, understandable, and ethical biometrics.
About Thales
Thales (Euronext Paris: HO) is a global leader in advanced technologies specialized in three business domains: Defence & Security, Aeronautics & Space, and Cybersecurity & Digital identity.
It develops products and solutions that help make the world safer, greener and more inclusive.
The Group invests close to €4 billion a year in Research & Development, particularly in key innovation areas such as AI, cybersecurity, quantum technologies, cloud technologies and 6G.
Thales has close to 81,000 employees in 68 countries. In 2023, the Group generated sales of €18.4 billion.
PLEASE VISIT
Thales Group
Digital Identity & Security
Thales
Thales Digital Identity and Security
View source version on businesswire.com: https://www.businesswire.com/news/home/20240915417415/en/
Contacts
PRESS CONTACTThales, Media Relations
PRESS CONTACTThales, Media Relations
Digital Identity and Security
Vanessa Viala
+33 (0)6 07 34 00 34
vanessa.viala@thalesgroup.com
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press release
Transaction advances portfolio transformation, sharpens focus on higher-growth, higher-margin businesses, strengthens balance sheet, and enhances value creation for shareholders IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio tr
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press release
Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapyBRUKINSA plus next-generation BCL2 inhibitor sonrotoclax (ZS) delivered deep, durable, and rapid uMRD responses, raising the bar for potential time-limited treatments in CLLData reinforce BeOne’s leadership in CLL and the strength of its foundational hematology franchise BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 pati
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom